Article
Cell Biology
Yimeng Zhang, Peng Ding, Yuanyong Wang, Changjian Shao, Kai Guo, Hanyi Yang, Yingtong Feng, Jiayi Ning, Minghong Pan, Ping Wang, Xiaolong Yan, Zhiqiang Ma, Jing Han
Summary: This study found that HDAC7 is overexpressed in choroidal melanoma tissues and promotes cell proliferation and metastasis, while inhibition of HDAC7 suppresses cell proliferation and metastasis. Furthermore, HDAC7 achieves its cancer-promoting effect in choroidal melanoma through the c-Myc signaling pathway.
CELL DEATH & DISEASE
(2023)
Article
Oncology
Beatrice Thier, Fang Zhao, Simone Stupia, Alicia Brueggemann, Johannes Koch, Nina Schulze, Susanne Horn, Christoph Coch, Gunther Hartmann, Antje Sucker, Dirk Schadendorf, Annette Paschen
Summary: The activation of RIG-I signaling in melanoma cells can induce dedifferentiation, but these dedifferentiated cells are still highly sensitive to autologous immune responses, challenging the concept of melanoma dedifferentiation as an indicator of T cell resistance.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Ihor Arkhypov, Feyza Gul Ozbay Kurt, Rebekka Bitsch, Daniel Novak, Vera Petrova, Samantha Lasser, Thomas Hielscher, Christopher Groth, Alisa Lepper, Xiaoying Hu, Wei Li, Jochen Utikal, Peter Altevogt, Viktor Umansky
Summary: Soluble HSP90 alpha can convert monocytes into MDSC, which inhibits the antitumor function of T and NK cells. Higher levels of HSP90 alpha in plasma of patients with melanoma are associated with increased PD-L1 expression on MDSC and shorter PFS after ICI therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Cell Biology
Cen Zhang, Juan Liu, Jianming Wang, Tianliang Zhang, Dandan Xu, Wenwei Hu, Zhaohui Feng
Summary: Hypoxia is crucial in solid tumors, with HIF and p53 signaling pathways playing key roles in regulating cellular responses to hypoxia. The interplay between hypoxia and p53 pathways can impact cancer progression, with p53 regulating hypoxia and HIF signaling in various ways, while mutant p53 can promote cancer progression through interaction with hypoxia and HIF signaling.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Medicine, Research & Experimental
Xinbo Huang, Mingxia Wang, Yuchen Liu, Yaoting Gui
Summary: This study developed an aptazyme switch that could sense wild-type p53 protein and flexibly regulate downstream gene function, achieving targeted killing effect on tumor cells in combination with other synthetic biological tools. The aptazyme successfully inhibited tumor growth by specifically recognizing p53 and provided a modular strategy for binding to cellular proteins.
Article
Oncology
Seemadri Subhadarshini, Sarthak Sahoo, Shibjyoti Debnath, Jason A. Somarelli, Mohit Kumar Jolly
Summary: The phenotypic heterogeneity of melanoma cells and its impact on adaptation to targeted therapy and immune checkpoint inhibitors were investigated using dynamical systems modeling and transcriptomic data analysis. A regulatory network involving transcription factors was constructed to understand the mechanisms behind phenotypic heterogeneity. The model predictions were validated experimentally in melanoma cell lines, demonstrating the potential for improved treatment of metastatic melanoma.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Immunology
Rachel L. G. Maus, Alexey A. Leontovich, Raymond M. Moore, Zachary Fogarty, Ruifeng Guo, Tara M. Davidson, Burak Tekin, Chathu Atherton, Jill M. Schimke, Betty A. Dicke, Benjamin J. Chen, Svetomir N. Markovic
Summary: This study used a spatial characterization method to evaluate tumor-immune interactions and found that the cellular composition of tumor and immune cell subsets in the tumor core was not associated with recurrence, but the spatial patterns were significantly different. It was also found that a cluster enriched with tumor and dendritic cells was associated with no recurrence. Further analysis found an enrichment of CTL-dendritic cell interactions in patients with no recurrence and CTL-macrophage interactions in patients with recurrence.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Karnoon Shamsoon, Daichi Hiraki, Koki Yoshida, Kiyofumi Takabatake, Hiroaki Takebe, Kenji Yokozeki, Naohiro Horie, Naomasa Fujita, Nisrina Ekayani Nasrun, Tatsuo Okui, Hitoshi Nagatsuka, Yoshihiro Abiko, Akihiro Hosoya, Takashi Saito, Tsuyoshi Shimo
Summary: The tumor microenvironment, particularly the Hh/Gli signaling, plays a crucial role in melanoma progression and treatment resistance. This study found high expression of Sonic Hedgehog, Gli1, and Gli2 in tumor cells, vasculatures, and osteoclasts of oral malignant melanoma specimens. Moreover, targeting Gli1 and Gli2 with a small-molecule inhibitor showed significant inhibition of bone destruction and abnormal angiogenesis in a mouse model.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Rui Shi, Zirong Liu
Summary: RPL15 plays crucial roles in the progression and metastasis of hepatocellular carcinoma (HCC), serving as a promising candidate for targeted therapies.
CANCER CELL INTERNATIONAL
(2022)
Article
Plant Sciences
Yu-Xi Liu, Ying-Jie Chen, Bo-Wen Xu, Xiu-Qiong Fu, Wen-Jun Ding, Sze-Man Amy Li, Xiao-Qi Wang, Jia-Ying Wu, Ying Wu, Xiaobing Dou, Bin Liu, Zhi-Ling Yu
Summary: This study demonstrates for the first time that chrysoeriol has anti-melanoma effects, partially through inhibiting STAT3 signaling. The results show that chrysoeriol can inhibit proliferation, migration, and survival of melanoma cells and induce apoptosis. Mouse studies also show that chrysoeriol can restrain melanoma growth, tumor-related angiogenesis, and alter the composition of immune cells in the melanoma microenvironment. These findings suggest that chrysoeriol has the potential to be developed as an anti-melanoma agent.
Review
Cell Biology
Md Ataur Rahman, Moon Nyeo Park, Md Hasanur Rahman, Md Mamunur Rashid, Rokibul Islam, Md Jamal Uddin, Md Abdul Hannan, Bonglee Kim
Summary: p53, the key tumor suppressor protein, plays a significant role in regulating various biological processes, including energy metabolism, cell cycle, apoptosis, and more. Autophagy, a crucial cellular process, is involved in maintaining cellular homeostasis. The relationship between p53 and autophagy is complex and not completely understood, as p53 can both inhibit and activate autophagy depending on its cellular localization and mode of action. Understanding the interaction between p53 and autophagy is important for cancer treatment and management.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Mayra A. Marques, Guilherme C. de Andrade, Jerson L. Silva, Guilherme A. P. de Oliveira
Summary: The p53 protein has dual functions as a tumor suppressor and as an oncogene, with its activities depending on cellular insults and mutational status, triggering opposing activities like cell death or survival, metabolic pathways, etc. It achieves a specific set of activities by enhancing or repressing specific target genes or interacting with cellular partners.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2022)
Article
Multidisciplinary Sciences
Duoli Zhang, Tao Zou, Qingsong Liu, Jie Chen, Mintao Xiao, Anfu Zheng, Zhuo Zhang, Fukuan Du, Yalan Dai, Shixin Xiang, Xu Wu, Mingxing Li, Yu Chen, Yueshui Zhao, Jing Shen, Guiquan Chen, Zhangang Xiao
Summary: METTL7A, a protein-coding gene associated with methylation, has been found to play an important role in tumor progression and tumorigenicity through the p53 signaling pathway.
Article
Cell Biology
Yuhan Zhang, Yan Chen, Lei Shi, Jie Li, Wenjuan Wan, Bowen Li, Doudou Liu, Xiaoshuang Li, Yuting Chen, Meng Xiang, Hao Chen, Bin Zeng, H. Rosie Xing, Jianyu Wang
Summary: The study demonstrates that extracellular vesicles (EVs) mediate the intercellular communication between melanoma stem cells (MSCs) and melanoma parental cells (MPCs), promoting metastasis through the miR-592/PTPN7/MAPK axis.
CELL DEATH DISCOVERY
(2022)
Review
Pharmacology & Pharmacy
Jing Huang
Summary: p53, one of the most well-studied tumor suppressors, is mutated or deleted in half of all cancers. Despite over forty years of research, designing therapeutics targeting the p53 pathway remains extremely challenging. Current efforts include developing p53-based gene therapy and targeted therapies, as well as exploiting the immunogenicity of p53 protein for cancer immunotherapy.
PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Multidisciplinary Sciences
Laura Codarri Deak, Valeria Nicolini, Masao Hashimoto, Maria Karagianni, Petra C. Schwalie, Laura Lauener, Eleni Maria Varypataki, Marine Richard, Esther Bommer, Johannes Sam, Stefanie Joller, Mario Perro, Floriana Cremasco, Leo Kunz, Emilio Yanguez, Tamara Husser, Ramona Schlenker, Marisa Mariani, Vinko Tosevski, Sylvia Herter, Marina Bacac, Inja Waldhauer, Sara Colombetti, Xavier Gueripel, Stephan Wullschleger, Melanie Tichet, Douglas Hanahan, Haydn T. Kissick, Stephane Leclair, Anne Freimoser-Grundschober, Stefan Seeber, Volker Teichgraber, Rafi Ahmed, Christian Klein, Pablo Umana
Summary: The study shows that PD1-IL2v can induce the differentiation of stem-like CD8(+) T cells into better effector cells by binding to PD-1, without the need for CD25 binding. PD1-IL2v has superior efficacy compared to PD-1 or PD-L1 blocking antibodies, as it avoids the accumulation of terminally differentiated and exhausted T cells.
Article
Immunology
Melanie Tichet, Stephan Wullschleger, Agnieszka Chryplewicz, Nadine Fournier, Rachel Marcone, Annamaria Kauzlaric, Krisztian Homicsko, Laura Codarri Deak, Pablo Umana, Christian Klein, Douglas Hanahan
Summary: PD1-IL2v is an engineered immunocytokine that delivers IL2v precisely to PD-1+ T cells in the tumor microenvironment, resulting in infiltration by stem-like CD8+ T cells and enhanced tumor regression and survival in mice. Combining PD1-IL2v with anti-PD-L1 improves therapeutic efficacy by reprogramming tumor-associated macrophages and enhancing T cell receptor immune repertoire diversity. These findings support the clinical evaluation of PD1-IL2v and anti-PD-L1 combination therapy in immunotherapy-resistant tumors infiltrated with PD-1+ stem-like T cells.
Article
Oncology
Lindsay B. Alcaraz, Aude Mallavialle, Caroline Mollevi, Florence Boissiere-Michot, Hanane Mansouri, Joelle Simony-Lafontaine, Valerie Laurent-Matha, Thierry Chardes, William Jacot, Andrei Turtoi, Pascal Roger, Severine Guiu, Emmanuelle Liaudet-Coopman
Summary: The study reveals that SPARC expression in cancer-associated fibroblasts (CAF) is an independent prognostic marker of poor outcome in triple-negative breast cancer (TNBC). The fibroblast-secreted SPARC also has a tumor-promoting role by inhibiting TNBC cell adhesion and stimulating their motility and invasiveness.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Editorial Material
Oncology
Michael Cerezo, Stephane Rocchi
Article
Clinical Neurology
Caroline Ruetsch-Chelli, Darin T. T. Okuda, Fanny Rocher, Sophie Tartare-Deckert, Marcel Deckert, Christine Lebrun-Frenay
Summary: This study investigated the effects of four S1P(1)-RM drugs approved for managing multiple sclerosis on melanoma cell lines in vitro and found that these drugs can promote the proliferation of melanoma cells at therapeutic concentrations. Therefore, increased dermatologic surveillance should be considered for patients with multiple sclerosis receiving S1P(1)-RM treatments.
NEUROLOGY AND THERAPY
(2023)
Letter
Hematology
Reinaldo Dal Bello, Kim Pacchiardi, Clementine Chauvel, Lionel Ades, Thorsten Braun, Justine Pasanisi, Elise Fournier, Celine Berthon, Emmanuelle Clappier, Emmanuel Raffoux, Delphine Lebon, Thomas Cluzeau, Christophe Roumier, Adriana Plesa, Karine Celli-Lebras, Herve Dombret, Claude Preudhomme, Stephanie Mathis, Alexandre Puissant, Claude Gardin, Raphael Itzykson
Article
Dermatology
Hanene Bzioueche, Katia Boniface, Claire Drullion, Sandrine Marchetti, Berengere Chignon-Sicard, Laura Sormani, Stephane Rocchi, Julien Seneschal, Thierry Passeron, Meri K. Tulic
Summary: Vitiligo is an autoimmune disease characterized by melanocyte loss and white patches on the skin. This study demonstrates that house dust mite (HDM) can induce inflammatory responses and melanocyte detachment in vitiligo through protease activity. HDM may act as an external source of pathogen-associated molecular pattern molecules in vitiligo, and MMP-9 inhibitors could be potential therapeutic targets. Furthermore, studying specific vitiligo endophenotypes can help understand the environmental contribution to the disease.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Kenji F. Shoji, Elsa Bayet, Sabrina Leverrier-Penna, Dahiana Le Devedec, Aude Mallavialle, Severine Marionneau-Lambot, Florian Rambow, Raul Perret, Aurelie Joussaume, Roselyne Viel, Alain Fautrel, Amir Khammari, Bruno Constantin, Sophie Tartare-Deckert, Aubin Penna
Summary: Melanoma, a highly aggressive cancer, is driven by aberrant cell motility behaviors and the ability to rapidly metastasize. This study reveals the prominent expression of the plasma membrane TRPV2 calcium channel in melanoma tumors, directly linked to metastatic dissemination. TRPV2 activity confers migratory and invasive potentials in both in vitro and in vivo settings, while silencing TRPV2 in highly metastatic melanoma cells prevents aggressive behavior. The TRPV2 channel, localized at the leading edge of invasive melanoma cells, regulates calcium-mediated activation of calpain and subsequent cleavage of talin, along with F-actin organization. Overexpression of TRPV2 in human melanoma tissues is associated with advanced malignancy and poor prognosis, suggesting its potential as a biomarker. By controlling adhesion and motility, the mechanosensitive TRPV2 channel offers a new therapeutic option for migrastatics in metastatic melanoma treatment.
Article
Biochemistry & Molecular Biology
Hanene Bzioueche, Myriam Tamelghaghet, Berengere Chignon-Sicard, Noemie Bazile, Pauline Hauchecorne, Maria Barbero Calderon, Pauline Meunier, Stephane Rocchi, Thierry Passeron, Meri K. Tulic
Summary: Ceramides are crucial for the barrier function of normal skin. Reduced ceramide levels are associated with atopic dermatitis. This study examined the impact of house dust mite (HDM) on skin integrity and the effect of different ceramides on HDM-induced skin damage. The presence of Ceramide AD (TM) in a cream inhibited HDM-induced damage and restored skin barrier function.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Serena Diazzi, Sophie Tartare-Deckert, Marcel Deckert
Summary: Advanced cutaneous melanoma is the deadliest form of skin cancer, and targeted therapies and immune checkpoint blockade therapies have revolutionized its treatment. However, therapy-driven resistance remains a significant challenge. Recent studies have shown that phenotypic plasticity of melanoma cells, particularly their ability to adapt mechanically, is a key factor in treatment resistance and tumor relapse. Targeting dedifferentiated cells and mechanotransduction pathways in the extracellular matrix (ECM) may hold promise in overcoming melanoma cross-resistance.
Article
Oncology
Kevin H. Lin, Justine C. Rutter, Abigail Xie, Shane T. Killarney, Camille Vaganay, Chaima Benaksas, Frank Ling, Gaetano Sodaro, Paul-Arthur Meslin, Christopher F. Bassil, Nina Fenouille, Jacob Hoj, Rachel Washart, Hazel X. Ang, Christian Cerda-Smith, Paul Chaintreuil, Arnaud Jacquel, Patrick Auberger, Antoine Forget, Raphael Itzykson, Min Lu, Jiaxing Lin, Mariaelena Pierobon, Zhecheng Sheng, Xinghai Li, Ashutosh Chilkoti, Kouros Owzar, David A. Rizzieri, Timothy S. Pardee, Lina Benajiba, Emanuel Petricoin, Alexandre Puissant, Kris C. Wood
Summary: The XPO1 inhibitor Selinexor activates PI3Ky-dependent AKT signaling in AML via upregulation of P2RY2, leading to positive antileukemic effects. Inhibiting this signaling pathway enhances the efficacy of Selinexor in AML.
Article
Multidisciplinary Sciences
Salima Benbarche, Cecile K. Lopez, Eralda Salataj, Zakia Aid, Cecile Thirant, Marie-Charlotte Laiguillon, Severine Lecourt, Yannis Belloucif, Camille Vaganay, Marion Antonini, Jiang Hu, Alexandra da Silva Babinet, Delphine Ndiaye-Lobry, Bryann Pardieu, Arnaud Petit, Alexandre Puissant, Julie Chaumeil, Thomas Mercher, Camille Lobry
Summary: This study reveals that fusion oncogenes like ETO2-GLIS2 can induce the activation of Super Enhancers (SEs) that regulate essential gene modules synergizing for leukemia progression, promoting the growth and survival of leukemia cells.